BLAINTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREALINJECTABLE
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
3/8 — Basic
PORTRAZZA (necitumumab) by Eli Lilly and Company is her1 antagonists [moa]. First approved in 2015.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PORTRAZZA (necitumumab) is a monoclonal antibody that antagonizes the epidermal growth factor receptor (HER1/EGFR), blocking ligand-driven signaling in cancer cells. It is administered intravenously as an injectable biologic therapy. The drug targets EGFR-expressing tumors across multiple indications.
Peak
Product is in peak commercial phase; teams are mature and optimized for sustained market presence with moderate competitive pressure (30/100).
Mechanism of Action
HER1 Antagonists
Pharmacologic Class:
Epidermal Growth Factor Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
Started Jan 2021
30 enrolled
Metastatic Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell CarcinomaStage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8+2 more
Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001
Started May 2018
1 enrolled
Squamous Cell Lung Cancer
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Started Nov 2016
0Locally Advanced Squamous Non-Small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung Cancer
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Started Oct 2016
29 enrolled
Non-small Cell Lung Cancer
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Started Oct 2015
54 enrolled
Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Worked on PORTRAZZA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.